Stocktoria

10x Genomics, Inc. TXG

Nasdaq · XNAS · stock · Laboratory Analytical Instruments · website · IPO 2019-09-12
Chart by TradingView
4/9
Piotroski F — financial health
1.63
Altman Z″ — distress risk · grey
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$642.8M$610.8M$618.7M$516.4M$490.5M
Gross profit$443.9M$414.5M$409.3M$396.0M$416.4M
Operating income-$61.0M-$194.6M-$265.3M-$167.9M-$52.3M
Net income-$43.5M-$182.6M-$255.1M-$166.0M-$58.2M
Operating cash flow$136.1M$6.7M-$15.2M-$33.6M-$21.4M
Free cash flow$130.1M-$5.7M-$63.8M-$165.3M-$122.7M
Total assets$1.0B$918.6M$965.1M$1.0B$1.0B
Total liabilities$245.0M$208.5M$224.1M$223.2M$201.3M
Shareholders' equity$796.3M$710.1M$741.0M$805.7M$817.6M
Ratios
Gross margin69.1%67.9%66.2%76.7%84.9%
Operating margin-9.5%-31.9%-42.9%-32.5%-10.7%
Net margin-6.8%-29.9%-41.2%-32.1%-11.9%
FCF margin20.2%-0.9%-10.3%-32.0%-25.0%
Return on assets-4.2%-19.9%-26.4%-16.1%-5.7%
Return on equity-5.5%-25.7%-34.4%-20.6%-7.1%
Current ratio4.464.974.694.856.77
Revenue growth5.2%-1.3%19.8%5.3%64.1%

Notable holders (13F)

InvestorSharesValue
ARK Investment Management LLC11,717,317$248.8M
RENAISSANCE TECHNOLOGIES LLC1,008,739$21.4M
Bridgewater Associates, LP35,101$745,194

Why these scores methodology →

Piotroski F-score: 4/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: 1.63 (grey)

  • Working capital / assets 0.51
  • Retained earnings / assets -1.451
  • EBIT / assets -0.059
  • Equity / liabilities 3.25

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001770787 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.